Total Visits

Views
Phase II multicenter study to analyze the predictive value of fusion gene TMPRSS2-ETS assessed both in tumor and blood sample, as a marker of response to enzalutamide in patients with metastatic castration resistant prostate cancer (CRPC) pre-chemotherapy73

Select a period of time:

Views

Views
July 202522
August 20259
September 20256
October 20253
November 20251
December 20252
January 20260
Download CSV file
 untranslated
 untranslated

Top country views

Views
Brazil18
United States8
United Kingdom6
South Africa2
Venezuela2
Canada1
Ecuador1
France1
Hungary1
Italy1
 

Top cities views

Views
Johannesburg2
Belo Horizonte1
Canoas1
Caracas1
Chapecó1
Clermont-Ferrand1
Crestline1
Cristalina1
Curitiba1
Dallas1